Security key
640671400
NEPHROS INC - Common stock, par value $0.001 per share (NEPH)
CUSIP: 640671400
Q2 2022 13F Holders as of 30 Jun 2022
- Security type / class
- Equity / Common stock, par value $0.001 per share
- Total 13F shares
- 632,473
- Total 13F value
- $968,000
- Share change
- -10,698
- SEC-reported price per share
- $1.53
- Number of holders
- 15
- Value change
- -$108,653
- Number of buys
- 9
- Number of sells
- 6
- Shares outstanding
- 10,851,408
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2022
Institutions
15
Top holders
10
NEPH full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
NEPHROS INC SEC filings
NEPHROS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 640671400
Recent filing periods:
Ownership snapshot
Top reported holders of NEPH - NEPHROS INC - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
WEXFORD CAPITAL LP
Disclosed value leader
WEXFORD CAPITAL LP
Comparable rows
0/15
Latest evidence
31 Mar 2022
13F
3/4/5
Highest disclosed value: $533,734,000
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
WEXFORD CAPITAL LP has the largest disclosed position value at $533.73M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens WEXFORD CAPITAL LP's linked filing trail.
Disclosed position value
Top 5
WEXFORD CAPITAL LP
$533.73M
BARD ASSOCIATES INC
$1.08M
VANGUARD GROUP INC
$541K
Cowen Prime Advisors LLC
$354K
Daron Evans
$351.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| WEXFORD CAPITAL LP |
13F
Company
|
—
denominator unverified
|
$533,734,000
3,663,969 shares
|
— | 31 Mar 2022 |
| BARD ASSOCIATES INC |
13F
Company
|
—
denominator unverified
|
$1,084,000
246,408 shares
|
— | 31 Mar 2022 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$541,000
122,978 shares
|
— | 31 Mar 2022 |
| Cowen Prime Advisors LLC |
13F
Company
|
—
denominator unverified
|
$354,000
80,400 shares
|
— | 31 Mar 2022 |
| Daron Evans |
3/4/5
CEO Specialty Renal Products
|
—
mixed-class rows
|
$351,795
179,718 shares
mixed-class rows
|
— | 24 May 2021 |
| HighTower Advisors, LLC |
13F
Company
|
—
denominator unverified
|
$245,000
55,710 shares
|
— | 31 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
15
Shares
632,473
Rows available
15
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2022 vs Q2 2026 Across Filers
Q2 2026 holders
33
Q2 2022 holders
15
Holder diff
-18
| Investor | Q2 2026 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q2 2026 value | Q2 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend